# A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

> **NCT07300085** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 100 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Fluzone HD influenza vaccine
- **COMBINATION_PRODUCT:** CD388 Injection
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07300085
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-08
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300085, "A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07300085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*